Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Joanne Quan Sells 6,911 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $90.27, for a total value of $623,855.97. Following the sale, the insider directly owned 11,305 shares in the company, valued at approximately $1,020,502.35. The trade was a 37.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Mirum Pharmaceuticals Stock Up 1.5%

Mirum Pharmaceuticals stock traded up $1.38 during mid-day trading on Wednesday, hitting $93.27. The company had a trading volume of 1,783,059 shares, compared to its average volume of 880,813. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $93.99. The company has a market capitalization of $4.79 billion, a PE ratio of -108.45 and a beta of 0.48. The stock’s 50 day moving average price is $75.89 and its two-hundred day moving average price is $69.99. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm’s revenue for the quarter was up 47.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.30) EPS. As a group, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Comerica Bank lifted its position in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the period. AQR Capital Management LLC increased its stake in shares of Mirum Pharmaceuticals by 307.3% in the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after acquiring an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after purchasing an additional 1,720 shares during the last quarter. Caxton Associates LLP acquired a new position in Mirum Pharmaceuticals during the first quarter valued at $217,000. Finally, Empowered Funds LLC boosted its holdings in Mirum Pharmaceuticals by 15.4% in the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after purchasing an additional 5,120 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have commented on MIRM. Cantor Fitzgerald restated an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. Robert W. Baird increased their price target on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Morgan Stanley boosted their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, December 9th. Citizens Jmp increased their target price on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research report on Friday, December 19th. Finally, TD Cowen raised Mirum Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, September 25th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $102.58.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.